|
|
Title:
Human renal stem cells
United States Patent: 7,776,592
Issued: August 17, 2010
Inventors: Wandinger-Ness;
Angela (Albuquerque, NM), Roitbak; Tamara (Albuquerque, NM), Romero; Elsa
G (Rio Rancho, NM)
Assignee: STC.UNM
(Albuquerque, NM)
Appl. No.: 11/469,265
Filed: August 31, 2006
|
|
|
Web Seminars -- Pharm/Biotech/etc.
|
Abstract
The present disclosure provides human
renal stem cells. Also described are human renal stem cells isolated from
the papillary region of the human kidney and methods of isolating the
same. Also described are methods for culturing, characterizing, and
differentiating the same, including methods for identifying human renal
stem cells that are positive for Nestin and CD133, and methods for
allowing the cells to differentiate into neurons.
Description of the
Invention
BACKGROUND OF THE INVENTION
Many renal disorders, including acute and chronic kidney disease, common
genetic diseases such as autosomal dominant polycystic kidney disease (ADPKD),
renal cell carcinoma, glomerulonephritis and other pathological
conditions, lead to kidney damage or loss. In the United States,
approximately one person in five reaching 65 years of age will undergo
organ-replacement during their remaining life span. It is predicted over 2
million patients will suffer from end-stage renal disease by 2010 [2].
Approximately 58,000 patients in the United States and 300 patients in New
Mexico are currently on the waiting list for a kidney transplant, with
some waiting for several years before an appropriate donor can be found.
Substantial fractions of patients (12-17%) on the waiting list are
designated as "most-difficult-to-transplant." Despite the advances in
kidney transplantation, a significant shortage of donor organs severely
limits treatment for these patients and requires many to remain on
dialysis for extended periods of time. The quest for alternate organ
restoration methods has resulted in rapid progression of new approaches,
such as therapeutic cloning and embryonic/adult stem cell therapy
(reviewed in 2-5).
The role of embryonic stem cells in the treatment of pathophysiological
disorders has recently attracted significant interest and has been the
subject of much controversy. The pluripotency of embryonic stem cells
presents the possibility of their use for replacement of damaged kidney
tissue. First indications show that mouse embryonic stem cells, develop an
endoderm-like tissue in culture and in kidney transplants [6]. However,
the in vitro generation of mesodermal precursors that give rise to the
adult kidney remains unsubstantiated.
Furthermore, the transplantation of ES cells includes potential
complications of immune rejection, teratomas and other cancers [4, 7]. The
problems associated with the use of embryonic stem cells and the potential
benefit of autologous transplantation has spurred an intensive search for
adult stem cell populations. It is increasingly clear that stem cells may
originate not only from embryonic, but also from adult tissue, including
adult brain, bone marrow, skin and gut, where they can be recruited for
organ repair after injury [8, 9]. Until recently, adult stem cells in
kidney had not been identified [2-4, 10]. Progenitor-like cells involved
in recovery from renal injury in an animal model were first identified in
2003 [11], and in 2004 a population of rodent adult kidney stem cells
derived from rat and mouse renal papilla was isolated and characterized
[1]. Adult rodent renal stem cells were identified on the basis of their
low cell division rate. To detect them, a pulse of bromodeoxyuridine (BrdU)
was administered to rat and mouse pups, and after 2-months, a small
population of BrdU-positive cells was detected in the renal papilla. These
cells had a plastic phenotype and, following injection into the renal
cortex, they incorporated into the parenchyma. Adult renal stem cells
exhibited features characteristic of other stem cells and expressed both
mesenchymal and epithelial proteins [1]. However, while rats and mice
serve as important animal models for human physiology, one cannot
necessarily predict from the results obtained in a rat or mouse model
system that the same results will be obtained in a human system. For
example, differing results may be obtained between an animal model, such
as rat and mouse, and the human system because of differences in the
immune systems, physiology, life spans, and/or hematopoetic pathways
between humans and rodents.
Another potential source for endogenous replacement of damaged or lost
renal tubular epithelia may be surviving tubular epithelial cells
themselves. These cells have a capacity to adapt to the loss of
neighboring cells through dedifferentiation and proliferation. Both
glomerular and tubular epithelial cells can regress to an embryonic
mesenchymal phenotype and can either stimulate a regenerative potential of
neighboring surviving cells or replace the damaged cells [10, 11]. A
functional role of these cells in organ repair is based on their ability
to migrate, proliferate and produce growth and trophic factors.
Accordingly, there remain many open questions regarding the
characteristics that define adult human renal stem cells, as well as their
precise differentiation potential. However, the identification of adult
human renal stem cells holds promise for numerous benefits including the
development of renal tissue replacement strategies.
DETAILED DESCRIPTION
The present disclosure provides a method for isolating adult human
papillary cells that display stem cell markers and exhibit the capacity to
differentiate toward different 20 lineages. The present disclosure further
provides methods for determining if the renal papilla in humans provides a
niche for a subpopulation of cells that serve as adult renal stem cells
and that are able to differentiate into fully differentiated tubular
epithelia.
There is general agreement that adult stem cells should exhibit continuous
self-renewal and the capacity to give rise to multiple differentiated cell
lineages [3]. Consequently, stem cells have the unusual property of being
able to undergo asymmetric cell division, wherein one progeny remains a
stem cell and the second progeny is a non-stem cell sister or transient
amplifying precursor that undergoes a finite number of divisions prior to
giving rise to fully mature, differentiated cells. Asymmetric DNA strand
segregation is believed to be a key component of asymmetric stem cell
division and serves to reduce the potential for mutation introduced by
errors during DNA replication [12]. As shown in FIG. 1 (see Original Patent),
in this scenario the chromosomes segregate non-randomly such that the stem
cell retains the original chromosome set, while the transient amplifying
precursor receives the newly replicated DNA. Such immortal DNA strand
cosegregation mechanisms have been shown to be operative in intestinal
cells and in cultured cell lines overexpressing p53 [9, 13, 14].
Relatively straightforward microscopic and flow cytometry based assays
have been developed to assess the asymmetric cell division properties of
stem cells based on such non-random DNA strand segregation [14].
For example, one microscopic assay is based on quenching of the
fluorescent Hoechst dye in the presence of DNA labeled by
bromodeoxyuridine. When cells are dividing symmetrically and labeled with
bromodeoxyuridine, followed by Hoechst dye, all cells exhibit uniformly
quenched Hoechst fluorescence. In contrast, if the bromodeoxyuridine
labeled cells undergo asymmetric division, the brornodeoxyuridine is lost
from the stem cell population and these cells are subsequently brightly
stained with Hoechst. The profile of bromodeoxyuridine label retention
measured by flow cytometry several passages after labeling may also reveal
a population of asymmetrically dividing cells. For example, if cells are
dividing symmetrically, all progeny will exhibit uniform label dilution.
If cells are dividing asymmetrically, a population of unlabeled cells is
expected.
Non-differentiated pluripotent cells, participating in kidney
regeneration, are expected to undergo major phenotypic transitions,
analogous to those occurring during normal kidney development. The major
difference being that in regenerating kidney, progenitor cells have to
undergo the necessary developmental stages to form new tubules in the
context of the adult, fully mature kidney. It is known that tubulogenesis
involves the integration of many cellular processes, such as
differentiation, polarization, shape change, proteolysis, growth, mitosis,
regulated cell death, motility, adhesion, signaling, ion fluxes,
cytoskeletal organization and membrane traffic [15]. Moreover, tubules can
be formed by cells under different conditions and induced by different
factors. To predict the behavior of non-differentiated pluripotent cells
in adult kidney, 2D filter cultures and 3D in vitro tubulogenesis models
may serve as useful experimental tools. Filter cultures enable optimal
cell polarization in vitro and are useful for monitoring the acquisition
of such epithelial hallmarks as apical and basolateral plasma membrane
polarity and transepithelial resistance due to the presence of tight
junctions [15]. At present, three-dimensional (3D) extracellular matrix
gel culture (composed of collagen I) is widely used for in-vitro
tubulogenesis studies [15]. This model provides an "in vivo-like" culture
condition and represents a simplified model for true tissue/organ
development.
An important and complicated stage in kidney repair is epithelial
redifferentiation, which requires a mesenchyme-to-epithelium transition of
progenitor cells, such as embryonic stem cells or dedifferentiated
survivor cells. Growth factors, including insulin-like growth factor-1
(IGF-1), hepatocyte growth factor (HGF) and epidermal growth factor (EGF),
in combination with matrix derived cues, most likely contribute to de-novo
generation of tubular epithelia. The search for actual inducing signals
that directly promote conversion of mesenchyme to epithelia is still in
process. Wnt proteins (particularly Wnt4) were implicated to be essential
for mesenchyme transition during tubulogenesis [16]. In addition, the
soluble tubulogenic factors, such as leukemia inhibitory factor (LIF),
transforming growth factor beta2 (TGF beta2), fibroblast growth factor 2
FGF2 (alone and in combination), were identified as the most striking
inducers of renal cell differentiation [17-19]. The ability of the cells
to respond to inductive signals depends on the expression of a number of
renal specific transcription factors such as WTI and Pax2, among others
[20, 21].
The key events in the recovery of renal tissue from injury are cell
dedifferentiation, proliferation and subsequent redifferentiation back
into fully polarized epithelial cells. Morphogenic processes that could
occur during kidney reconstruction (mediated by dedifferentiated surviving
cells or transplanted embryonic stem cells) would be highly dependent on
the expression of proteins, implicated in renal tissue development. Among
these, members of the cadherin super-family are likely to play a critical
role [10]. Several cadherins, such as E-cadherin, R-cadherin, cadherin-6,
cadherin-1 1, N-cadherin and P-cadherin, are expressed during
nephrogenesis [22]. In addition, the kidney-specific cadherin 16 has
recently been implicated in the differentiation of adult stem-like cells
from mouse kidney [23].
Cadherin-mediated adhesion is critical during embryogenesis, morphogenesis
and in the normal function of epithelial tissues. Cadherins promote
Ca2+-dependent cell-cell adhesion through hemophilic interactions with
cadherins on neighboring epithelial cells [24,25]. Via their carboxy-terminal
cytoplasmic tail, classical cadherins associate with cell cytoskeletal
molecules. For example, E-cadherin, which is highly expressed in
epithelia, associates with .beta.-catenin and .alpha.-catenin to promote
interaction with the actin cytoskeleton [25-27]. The E-cadherin/.beta.-catenin
complex plays a dual role. On the one hand, it stabilizes cellular
adhesion through cytoskeletal attachment and on the other hand, the
protein complex modulates signal transduction and consequently imparts
gene expression and cell cycle control. During the process of mesenchyme-to-epithelium
transition in kidney organogenesis, N-cadherin is replaced by E-cadherin
[28]. Expression of different cadherins and so-called cadherin switches
(when one of the cadherins is replaced by another member of the same
cadherin protein family) is temporally and spatially regulated during
kidney development. This precisely regulated expression is implicated in
such critical stages as initial aggregation of mesenchymal cells,
mesenchyme-to-epithelium transition, cell proliferation, migration,
adhesion and other complex signaling events leading to the formation of
mature nephrons.
In vivo animal studies have been used to complement in vitro
differentiation analyses and provide critical information regarding the
ability of stem cells to repopulate specific tissues. Bone marrow derived
hematopoietic stem cells have been studied most extensively with animal
studies being used to demonstrate pluripotency [29]. Thus, cells were
shown to differentiate not only into the hematopoietic lineage, but also
to give rise to epithelia of the liver, lung and gut. In the case of
kidney, there is conflicting evidence as to the potential of circulating
hematopoietic stem cells to contribute to renal repair [30, 31]. The most
recent study suggests that increased cytokine levels enhance kidney
recovery following ischemic injury by reducing inflammation rather than by
increasing the incorporation of bone marrow derived cells into regenerated
tubules [31]. The quest to identify and characterize kidney-derived stem
cells has also relied on animal models. Rodent renal ischemic injury
models have been used to provide evidence for a direct role of tubular
epithelial cells in tubule regeneration [11], as well as to support the
role of rodent papillary cells in kidney regeneration [1]. Stem cell
transplantation with or without renal injury has in turn been used to
monitor the capacity of the implanted cells to reintegrate within the
intact kidney [1, 32]. In one such study, human CD133 positive cells were
xenotransplanted to a SCID mouse following induction of renal ischemia by
glycerol injection and the incorporation of the human cells into kidney
tubules was scored [32]. At present, the nature and identity of the
progeny of renal papillary cells in vivo remains an open question. On the
whole, establishing the optimal conditions for induction of
differentiation, as well as elucidating the requisite protein expression
profiles involved in restoration of injured kidneys, is of particular
importance for successful implementation of renal stem cell therapy. There
are a number of potential therapeutic applications for stem cells in the
future. One is the possible introduction of multipotent cells of different
origins for replacement of damaged nephrons following renal injury and
monitoring the regenerative process. Another is genetic modification of
multipotent cells (stable expression of a selected protein) and their
implantation into host renal tissues. This approach may offer improved
control over indiscriminate direct injections of gene vectors [10]. The
correction of genetic defects would be helpful for the treatment of
inherited renal diseases, such as ADPKD. Further, cell therapy could be
used as more direct approach for effective delivery of therapeutic drugs.
Pluripotent cells, such as adult and embryonic stem cells or
dedifferentiated kidney cells, have a rare natural capability of
regenerating damaged tissue. Cell therapy will be one of the most advanced
therapeutic tools in the nearest future. Tissue based therapy will also
support presently used methods, such as kidney transplantation, where
genetically modified pluripotent cells may contribute to minimizing
immunologic rejection of the transplanted kidney.
As stated above, according to one embodiment, the present invention
includes methods for the isolation of renal papillary cells and/or renal
stem cells. Such cells may be isolated from one or more human kidneys. As
used herein, the term "isolated" means that a cell population is removed
from its natural environment. As used herein, the term "purified," means
that a cell population is essentially free from any other cell type.
The cells of the present invention may be isolated from a region deep
within the inner medullary region of the kidney. In situ in the kidney,
the cells of the present invention may reside within the loops of Henle,
the tubules found deep within the kidney papilla.
According to another embodiment, the present invention also includes
isolated cells populations with a marker staining pattern similar to the
marker staining pattern of isolated human renal papillary cells, wherein
the cell populations are isolated from a cell source other than the renal
papillary region of a human kidney. Such populations may be isolated, for
example, from placental cord blood, bone marrow, embryonic stem cell
populations, neonatal stem cell populations, and/or somatic stem cell
populations. Such markers may include, but are not limited to CD133 and
nestin.
According to yet another embodiment, the present invention also includes
methods of culturing, co-culturing, maintaining and/or storing isolated
human renal papillary cells so that further differentiation does not
occur.
The isolated human renal papillary cells described herein may possess the
ability to differentiate into specialized cells having one or more
structural and/or functional aspects of a physiologic kidney. The present
invention also includes methods of culturing, co-culturing maintaining
and/or storing isolated human renal papillary cells so that
differentiation occurs. For example, hypoxic conditions, ischemic injury,
or conditions mimicking ischemic injury may be used to induce isolated
human renal papillary cells to differentiate. As another example, the
isolated human renal papillary cells may be co-cultured with other types
of cells, such as differentiated adult human kidney tubule cells or
embryonic neural stem cells. Accordingly, using various methods described
herein, isolated human renal papillary cells may be induced to
differentiate into different types of cells such as, for example, into
tubular epithelial cells or neuronal cells. According to still another
embodiment, the present invention also includes such populations of
differentiated cells.
The isolated human renal papillary cells described herein possess the
ability to differentiate into specialized cells having one or more
structural and/or functional aspects of a physiologic kidney. For example,
isolated human renal papillary cells may be induced to differentiate into,
for example, tubular epithelial cells or may be used to repopulate kidney
tubules.
According to another embodiment, the present invention also includes gene
expression profiles of isolated human renal papillary cells. Such gene
expression profiles may be used in the identification of markers for stem
cells. Such gene expression profiles may be used for monitoring, for
example, proliferative potential and differentiation status of stem cells.
Such gene expression profiles include, but are not limited to, gene
expression profiles from undifferentiated cell populations, gene
expression profiles from differentiated cell populations, and gene
expression profiles from cell populations obtained from individuals.
Individuals from which gene expression profiles may be obtained include,
but are not limited to, individuals with normal kidney function,
individuals suffering from a kidney disorder, individuals suspected of
carrying one or more genes for a heritable kidney condition, individuals
undergoing treatment for a kidney disorder, and individuals undergoing
treatments with nephrotoxic side effects. Gene expression profiles may be
obtained by any known methods. For example, gene expression profiles may
be obtained using the Human Genome U133 Plus 2.0 Genechip.RTM. Array (Affymetrix,
Santa Clara, Calif.).
According to yet another embodiment, the isolated human renal papillary
cells disclosed herein may be administered to a subject for the treatment
of a kidney disorder. The cells to be administered include
undifferentiated cells and/or cells that have been induced to
differentiate.
According to some embodiments, the isolated human renal papillary cells
disclosed herein may include an exogenous polynucleotide. According to
some embodiments, the exogenous polynucleotide may encode a therapeutic
agent. According to another embodiment, the exogenous polynucleotide may
include an expression vector.
According to a still further embodiment, the isolated human renal
papillary cells of the present invention may be used in bioartificial
kidneys such as, for example, the bioartificial kidney described in U.S.
Pat. No. 6,150,164.
Those of skill in the art will be familiar with a wide variety of
materials and methods that are suitable for use to perform the methods
described in the present disclosure. For example, suitable materials and
methods include, but are not limited to those described in U.S. Pat. Nos.
5,429,938; 6,060,270; 6,150,164; 6,410,320; and 6,458,588; and U.S. Patent
Application Serial No. 20020119566 A1.
As stated above, according to one embodiment of the present invention, a
potential adult stem cell population has been isolated and characterized
from human kidney papilla. The cells occupy a niche that is deep within
the inner medulla and relatively hypoxic providing protection against
oxidative stress. Preliminary ultrastructural analyses show these cells in
situ exclusively in the loops of Henle of tubules found deep within the
kidney in papilla. The cells are embedded between the tubular epithelia
and have a characteristic morphology with large nuclei and a limited
cytoplasm that is readily distinguishable from that of tubular epithelial
cells. These putative adult human renal stem cells express markers that
are characteristic of stem cells, including CD133 and nestin. In the
presence of serum or specific growth factors the cells are able to adopt
tubular epithelial-like or neuronal-like phenotypes. In vitro studies show
the papillary cells readily associate with cortical tubular epithelia,
both on filter cultures and in 3D collagen gel cultures, and in
serum-free, 2D cultures form structures resembling neurospheres.
Various methods for demonstrating that a subpopulation of human papillary
cells constitutes adult renal stem cells that can differentiate into
tubular epithelia are described below. Methods for characterizing isolated
human papillary cells for their self-renewal potential, ability to give
rise to tubular epithelia and their ability to repopulate kidney tubules
are also described. At present there is limited information about the
origin and identity of adult renal stem cells, making the work highly
relevant for the development of tissue engineering and alternate renal
tissue repair strategies.
Self-Renewal Potential and Asymmetric DNA Segregation
Two hallmarks ascribed to bona fide stem cells is their ability to undergo
indefinite self-renewal and asymmetric DNA strand segregation. To assay
self-renewal potential, primary human papillary cells can be maintained in
culture under conditions designed to maximize the maintenance of
undifferentiated multipotent adult progenitor cells. The cells can be
continuously cultured and passaged prior to confluence. By measuring the
cell number at each passage and monitoring the number of passages we can
establish if renal papillary, CD133 and nestin positive cells can be
maintained in culture long-term, for example, logarithmic growth for up to
one year. Cells can be screened by flow cytometry for various markers of
cell differentiation at the start and at defined intervals. Microscopic
and flow cytometry based assays can be used to assess the potential for
asymmetric DNA segregation. These studies enable the distinction between
isolated human papillary cells that resemble a bona fide stem cell
population and cells that are transient amplifying precursor cells.
Pluripotent Phenotype and Ability to Differentiate into Tubular Epithelia
A third hallmark ascribed to stem cells is the ability to give rise to
cell populations with various differentiated phenotypes. In vitro cell
differentiation assays can be used to characterize the potential of the
isolated papillary cells to yield distinct cell populations with a
particular emphasis on their ability to differentiate into tubular
epithelia. In vitro, 2D filter cultures and 3D extracellular matrix gel
systems are widely used to study renal tubule epithelial cell function.
Epithelial cells grown on 2D filter cultures form cellular junctions and
establish a transepithlial resistance. Epithelial cells, grown in 3D
collagen gel cultures, form complex cyst-like or tubule-like epithelial
structures. 2D and 3D cell cultures supplemented with select growth
factors or tubulogenic factors can be studied as a function of time. To
assess differentiation status, cell morphology, expression of
differentiation specific markers, transepithelial resistance and
tubulogenesis can be analyzed. Once a bona fide renal stem cell population
is identified, a renal stem cell gene expression profile can be
established relative to fully differentiated tubular epithelia to
facilitate future stem cell isolation and characterization. Studies
monitoring the differentiation potential of human papillary progenitor
cells can provide insights into the possible utility of these cells in
renal tubular epithelial tissue regeneration.
Contribution to Tubular Regeneration
A fourth hallmark ascribed to stem cells is in vivo regenerative capacity
following renal injury. Such analyses necessitate animal studies. Pilot
studies can be performed with xenotransplanted, immunosuppressed rats to
evaluate the optimal model for in vivo functional analyses of the
differentiation and regenerative potential of the putative human papillary
stem cells. The incorporation of labeled human cells into various tubules
versus the kidney parenchyma can be quantified, as can the dependence on
renal injury for incorporation. An optimal animal model system can thus be
defined, laying the foundations for more detailed animal studies.
Various embodiments of the present invention are illustrated by the
following examples. It is to be understood that the particular examples,
materials, amounts, and procedures are to be interpreted broadly and as
non-limiting. Accordingly, it will be appreciated that while may of the
examples included herein describe the use of specific instruments, assay
reagents, assay systems, material sources, etc., those of skill in the art
will be familiar with many instruments, assay reagents, assay systems,
material sources, and the like, which will or could be used for the same
purposes. Accordingly, such description is intended to be exemplary in
nature and should not be interpreted as limiting the invention to any of
the specifically described instruments, assay reagents, assay systems,
material sources etc.
Claim 1 of 8 Claims
1. Isolated human renal adult stem cells,
where the human renal stem cells were isolated from only the papillary
region of human kidney, wherein the renal adult stem cells are surface
positive for CD133 and intracellular nestin. ____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|